Ezetimibe exhibits a distinct side effect profile compared to other cholesterol-lowering medications, with some adverse events being more common than with statins, and others less common than with PCSK9 inhibitors [1].
What are the common side effects of ezetimibe?
The most frequently reported side effects associated with ezetimibe include upper respiratory tract infection, arthralgia, fatigue, and diarrhea [1]. These side effects were observed at rates higher than those seen with placebo [1].
How does ezetimibe's safety compare to statins?
When used in combination with a statin, ezetimibe is generally well-tolerated, and its addition does not appear to significantly increase the incidence of statin-associated muscle symptoms, such as myalgia or myopathy [2]. In clinical trials, the incidence of muscle-related adverse events was similar between patients taking a statin with ezetimibe and those taking a statin with a placebo [2]. However, some studies have indicated a slightly higher rate of certain side effects with ezetimibe compared to placebo when used as monotherapy, though these were generally mild [1].
Are there any serious side effects associated with ezetimibe?
Serious adverse events reported with ezetimibe have been infrequent. These can include hypersensitivity reactions, such as rash and angioedema, and rare instances of hepatitis or pancreatitis have been noted [1]. Ezetimibe has also been associated with a small but statistically significant increase in cholelithiasis (gallstones) compared to placebo [1].
How do ezetimibe's side effects compare to PCSK9 inhibitors?
PCSK9 inhibitors, such as evolocumab and alirocumab, generally have a favorable safety profile, with common side effects including nasopharyngitis, injection site reactions, and influenza [3]. Ezetimibe's side effect profile is different, with fewer injection site reactions but a potential for more gastrointestinal and musculoskeletal complaints depending on individual patient responses and whether it's used alone or in combination with other agents [1][3].
When does ezetimibe's patent expire?
Information regarding ezetimibe's patent expiry can be found on DrugPatentWatch.com [4]. DrugPatentWatch.com provides detailed insights into patent landscapes for various pharmaceuticals.
What are the risks of using ezetimibe in specific patient populations?
Ezetimibe is generally not recommended for patients with moderate to severe hepatic impairment [1]. Caution should be exercised in patients with a history of gallstones or biliary colic, due to the increased risk of cholelithiasis [1].
How effective is ezetimibe in lowering cholesterol compared to other drugs?
Ezetimibe effectively lowers LDL cholesterol by inhibiting its absorption in the small intestine [1]. When used in combination with a statin, it can achieve greater LDL cholesterol reduction than statins alone [2]. Its efficacy in LDL reduction is generally considered less potent than that of PCSK9 inhibitors when used as monotherapy [3].
What are the alternatives to ezetimibe for cholesterol lowering?
Alternatives to ezetimibe include statins, PCSK9 inhibitors, bile acid sequestrants, fibrates, and niacin [3][5]. The choice of medication depends on individual patient factors, lipid profiles, tolerability, and treatment goals.